- Swiss healthcare provider Hôpitaux Universitaires Genève (HUG) becomes the first European university hospital to use IBM Watson for Genomics.
- IBM Watson for Genomics leverages AI to provide expertly validated, up-to-date, comprehensive content to enable clinical reporting & precision oncology programs.
- The HUG is Switzerland's leading center for influenza and emerging viral infections, as well as for childhood liver disease and pediatric liver
Read More
FDA Cancer OCE, Syapse Partner on Regulatory Use of Real-World Evidence (RWE)
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multi-year Research Collaboration Agreement (RCA) focused on the use of real-world evidence (RWE) to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to address key regulatory questions about testing and treatment patterns, dosing and safety, and outcomes in oncology, with a focus on precision medicine.Methods to Derive RWE From Multiple
Read More
SHUH, Syapse to Build South Korea’s First Real-World Data Sharing Network for Precision Oncology Hospitals
SNUH and Syapse will collaboratively work towards building South Korea’s first real-world data-sharing network for leading precision oncology hospitals in the region. Syapse, a company accelerating precision medicine through insights derived from its global health system network, and Seoul National University Hospital (SNUH), a South Korea-based hospital, today announced that they have extended their partnership with a new multi-year agreement. As part of their partnership, SNUH and Syapse will
Read More
Pfizer, Syapse Partner on Oncology Precision Medicine Using Real-World Evidence (RWE)
Syapse, a San Francisco, CA-based precision medicine company, today announced that it has entered into a strategic collaboration with Pfizer to advance cancer outcomes research using real-world evidence (RWE) toward the ultimate goal of improving patient health. This collaboration will initially focus on the molecular testing and therapy choices on precision oncology journeys in the healthcare system setting.Syapse NetworkThe Syapse Network enables health systems and their providers to learn
Read More
Tempus, Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas
Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas (TCGA) Project for submission to the National Cancer Institute’s Genomic Data Commons (GDC).The Cancer Genome Atlas (TCGA) Project BackgroundThere are 230 distinct investigators that contributed
Read More
Amgen, Syapse Partner to Develop Observational Research Analytics for Precision Oncology
Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, today announced a precision medicine collaboration in oncology. Under the terms of the collaboration, Amgen and Syapse will develop observational research analytics to assess treatment outcomes for areas of unmet need in oncology.Generates Insights from Real-World Evidence for Potential Use in Regulatory FilingsThis effort will identify existing patients within
Read More
Pfizer & Concerto HealthAI Team Up on Precision Oncology Collaboration
Concerto HealthAI announced a deal
with Pfizer, through which Pfizer will
harness Concerto HealthAI’s eurekaHealth AI platform
and real-world data (RWD) to help identify new and more precise treatment
options as well as accelerate completion times for various outcomes studies. Concerto
HealthAI is comprised of the leading healthcare data scientists, health
economists, epidemiologists, and AI software engineers to advance flexible and
increasingly enterprise grade solutions for advancing RWE into
Read More
March 2019 News, Merger & Acquisition, IPO, Public Company Performance Summary
A brief summary of noteworthy news, health IT M&A activity, IPOs, and public company performance during the month of March.
Noteworthy News
Amazon, JP Morgan, Berkshire Names New Joint Venture Haven
Amazon, J.P. Morgan, and Berkshire Hathaway name joint venture Haven. In January 2018, the three founding companies announced plans to create this independent organization, now called Haven, which is free from profit-making incentives and constraints. Haven’s focus is the 1.2 million
Read More
Guardant Health to Acquire Cancer Diagnostic Company Bellwether Bio
Precision oncology company Guardant Health, Inc., announced that it
has entered into a definitive agreement to acquire
Seattle-based Bellwether Bio, an
oncology startup developing next generation cancer diagnostics using cell-free
DNA. The acquisition is expected to close in April 2019. Financial terms of the
acquisition were not disclosed.
Bellwether Bio Background
Spun out of the University of Washington in 2016, Bellwether
Bio (formerly known as Haverhill Genetics) is developing
Read More
ICON Acquires Precision Medicine for Oncology Company MolecularMD
ICON, a global provider of drug development solutions and services has acquired MolecularMD, a molecular diagnostic specialty laboratory that enables the development and commercialization of precision medicines in oncology. The acquisition of MolecularMD’s extensive scientific and clinical biomarker experience expands the ICON’s capabilities in molecular diagnostic testing and also adds expanded testing platforms, including next-generation sequencing and immunohistochemistry, to ICON’s
Read More